Altretamine

• CAT Number: A000197
• CAS Number: 645-05-6
• Molecular Formula: C9H18N6
• Molecular Weight: 210.28
• Purity: ≥95%
• Target: DNA Alkylating
• Solubility: >8.85mg/mL in DMSO
• Storage: -20°C
• InChI: 1S/C9H18N6/c1-13(2)7-10-8(14(3)4)12-9(11-7)15(5)6/h1-6H3
• InChIKey: UUVWYPNAQBNQJQ-UHFFFAOYSA-N
• SMILES: CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C

Altretamine is a synthetic cytotoxic s-triazine derivative similar in structure to alkylating agent triethylenemelamin with antineoplastic activity. Although the precise mechanism by which altretamine exerts its cytotoxic effect is unknown, N-demethylation of altretamine may produce reactive intermediates which covalently bind to DNA, resulting in DNA damage. Check for active clinical trials or closed clinical trials using this agent.

Reference

1: Gidwani B, Vyas A. Pharmacokinetic study of solid-lipid-nanoparticles of
altretamine complexed epichlorohydrin-β-cyclodextrin for enhanced solubility and
oral bioavailability. Int J Biol Macromol. 2017 Aug;101:24-31. doi:
10.1016/j.ijbiomac.2017.03.047. Epub 2017 Mar 14. PubMed PMID: 28315435.

2: Gidwani B, Vyas A. Preparation, characterization, and optimization of
altretamine-loaded solid lipid nanoparticles using Box-Behnken design and
response surface methodology. Artif Cells Nanomed Biotechnol. 2016;44(2):571-80.
doi: 10.3109/21691401.2014.971462. Epub 2014 Nov 3. PubMed PMID: 25363752.

3: Kelner MJ, McMorris TC, Rojas RJ, Estes LA, Suthipinijtham P. Synergy of
irofulven in combination with other DNA damaging agents: synergistic interaction
with altretamine, alkylating, and platinum-derived agents in the MV522 lung tumor
model. Cancer Chemother Pharmacol. 2008 Dec;63(1):19-26. doi:
10.1007/s00280-008-0703-0. Epub 2008 Feb 28. PubMed PMID: 18305940.

4: Alberts DS, Jiang C, Liu PY, Wilczynski S, Markman M, Rothenberg ML. Long-term
follow-up of a phase II trial of oral altretamine for consolidation of clinical
complete remission in women with stage III epithelial ovarian cancer in the
Southwest Oncology Group. Int J Gynecol Cancer. 2004 Mar-Apr;14(2):224-8. PubMed
PMID: 15086720.

5: Chan JK, Loizzi V, Manetta A, Berman ML. Oral altretamine used as salvage
therapy in recurrent ovarian cancer. Gynecol Oncol. 2004 Jan;92(1):368-71. PubMed
PMID: 14751188.

6: Keldsen N, Havsteen H, Vergote I, Bertelsen K, Jakobsen A. Altretamine
(hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer: a
phase II study. Gynecol Oncol. 2003 Feb;88(2):118-22. PubMed PMID: 12586589.

7: Olver I, Davy M, Lüftner D, Park SH, Egorin M, Ellis A, Webster L. A phase I
study of paclitaxel and altretamine as second-line therapy to cisplatin regimens
for ovarian cancer. Cancer Chemother Pharmacol. 2001 Aug;48(2):109-14. PubMed
PMID: 11561776.

8: Zon RT, McClean J, Helman D, Ansari R, Picus J, Sandler A, Williams SD,
Loehrer PJ Sr. Altretamine for the treatment of metastatic renal cell carcinoma.
A Hoosier Oncology Group trial. Invest New Drugs. 2001;19(3):229-31. PubMed PMID:
11561679.

9: Rothenberg ML, Liu PY, Wilczynski S, Hannigan EV, Weiner SA, Weiss GR, Hunter
VJ, Chapman JA, Tiersten A, Kohler PC, Alberts DS. Phase II trial of oral
altretamine for consolidation of clinical complete remission in women with stage
III epithelial ovarian cancer: a Southwest Oncology Group trial (SWOG-9326).
Gynecol Oncol. 2001 Aug;82(2):317-22. PubMed PMID: 11531286.

10: Malik IA. Altretamine is an effective palliative therapy of patients with
recurrent epithelial ovarian cancer. Jpn J Clin Oncol. 2001 Feb;31(2):69-73.
PubMed PMID: 11302345.